#CardioMastodon #Glucagonlikepeptide 1 receptor agonists (GLP1-RA) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) were individually proven to reduce major adverse cardiovascular events (MACE) in #T2DM patients, but the relative magnitude of benefits from these two drug classes is debated.
📌https://pubmed.ncbi.nlm.nih.gov/35195376/
📌 https://www.nmcd-journal.com/article/S0939-4753(12)00122-6/fulltext